2.5
2025

Multicenter survey on eosinophilic esophagitis in Italy: trends in diagnosis, diagnostic delay, and type 2 comorbidity burden

Show more: Authors information and Publication history
Authors Information

1SOSD Allergy and Immunology, Prato-Pistoia, Italy

2Allergology Unit, IRCCS San Martino Polyclinic Hospital, Genoa, Italy

3Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Italy

4Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy

5Immunology and Allergy Unit, S. Maria degli Angeli Hospital, Pordenone, Italy

6SSI Allergology Romagna Health Authority, Rimini Hospital, Rimini, Italy

7Allergy Unit, Azienda Ospedaliera S. Giuseppe Moscati, Avellino, Italy

8Clinic Immunology Unit, Policlinico Umberto I, Rome, Italy

9Allergologist, BIOS Spa, Rome, Italy

History

Published: 25 June 2026
Accepted: 12 June 2026
Received: 10 March 2026

SUMMARY

Background. Eosinophilic esophagitis (EoE) is a chronic, immune-mediated esophageal disorder that has been increasingly recognized over recent decades. It is characterized by a type 2 inflammatory response, shared with other type 2 inflammatory conditions such as allergic rhinitis (AR), food allergy (FA), atopic dermatitis (AD), bronchial asthma (BA), and chronic rhinosinusitis with nasal polyps (CRSwNP). Methods. A total of 295 patients with EoE, followed at seven Italian allergy centers with expertise in managing EoE, were included. We analyzed annual EoE diagnoses, diagnostic delay, and the presence of type 2 comorbidities – including AR, FA, BA, AD and CRSwNP – assessed via allergological evaluations at the participating centers. Statistical analyses included non-parametric trend tests, linear and logistic regressions, chi-square tests, and descriptive analyses. Results. Annual EoE diagnoses showed a significant upward trend from 2014 to 2024 (p = 0.002). However, the diagnostic delay remained consistently high, showing no corresponding reduction despite the rise in diagnoses. The burden of type 2 comorbidities was substantial, with 83.4% of patients presenting at least one comorbidity, and most patients exhibited multiple comorbidities. Conclusions. Our findings are consistent with previously reported increases in EoE diagnoses in Italy, alongside persistent diagnostic delays, and highlight the substantial burden of type 2 comorbidities in these patients, emphasizing the importance of systematic allergological evaluation and multidisciplinary managementin patients with EoE.

KEY WORDS
Eosinophilic esophagitis; type 2 comorbidity; allergic comorbidities; type 2 inflammation; diagnostic delay.

Table of Content: Online First

European Annals of Allergy and Clinical Immunology ISSN 1764-1489 | ©2026